Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Biosimilars in Dermatology

Biosimilars in Dermatology Opinion EDITORIAL Mark Lebwohl, MD Biosimilars are large complex molecules that are highly simi- et al. The infliximab biosimilar trial reported by Westerkam lar in structure and function to the approved brand-name mol- et al compared 20 patients receiving originator infliximab ecules known as biologics. Biosimilars currently approved in and 14 patients receiving a biosimilar. Although many of the study end points were not statistically significant between the United States that could be used by dermatologists include those for rituximab, the treatment groups, the authors acknowledge that the etanercept, adalimumab, and study was limited by its small sample sizes, retrospective Related articles infliximab. Other approved analysis of data, and allowance of concomitant medications. biosimilars include those for pegfilgrastim, bevacizumab, The authors also acknowledge that, because copay assis- trastuzumab, filgrastim, and epoetin alpha. tance was available for the originator but not for the bio- This issue of JAMA Dermatology includes 2 articles similar, selection bias may have occurred. Despite the small assessing biosimilars of tumor necrosis factor blockers that size of the study, visual analog scale pain scores were more are used to treat a number of dermatologic and nonderma- statistically significantly improved for the patients who tologic conditions. Loft http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Biosimilars in Dermatology

JAMA Dermatology , Volume 157 (6) – Jun 7, 2021

Loading next page...
 
/lp/american-medical-association/biosimilars-in-dermatology-ndRf0iTpVe
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2021.0219
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Mark Lebwohl, MD Biosimilars are large complex molecules that are highly simi- et al. The infliximab biosimilar trial reported by Westerkam lar in structure and function to the approved brand-name mol- et al compared 20 patients receiving originator infliximab ecules known as biologics. Biosimilars currently approved in and 14 patients receiving a biosimilar. Although many of the study end points were not statistically significant between the United States that could be used by dermatologists include those for rituximab, the treatment groups, the authors acknowledge that the etanercept, adalimumab, and study was limited by its small sample sizes, retrospective Related articles infliximab. Other approved analysis of data, and allowance of concomitant medications. biosimilars include those for pegfilgrastim, bevacizumab, The authors also acknowledge that, because copay assis- trastuzumab, filgrastim, and epoetin alpha. tance was available for the originator but not for the bio- This issue of JAMA Dermatology includes 2 articles similar, selection bias may have occurred. Despite the small assessing biosimilars of tumor necrosis factor blockers that size of the study, visual analog scale pain scores were more are used to treat a number of dermatologic and nonderma- statistically significantly improved for the patients who tologic conditions. Loft

Journal

JAMA DermatologyAmerican Medical Association

Published: Jun 7, 2021

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month